Back to Search
Start Over
Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
- Source :
-
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2012 May; Vol. 54 (9), pp. 1364-72. Date of Electronic Publication: 2012 Mar 28. - Publication Year :
- 2012
-
Abstract
- Background: The lower tuberculosis incidence reported in human immunodeficiency virus (HIV)-positive individuals receiving combined antiretroviral therapy (cART) is difficult to interpret causally. Furthermore, the role of unmasking immune reconstitution inflammatory syndrome (IRIS) is unclear. We aim to estimate the effect of cART on tuberculosis incidence in HIV-positive individuals in high-income countries.<br />Methods: The HIV-CAUSAL Collaboration consisted of 12 cohorts from the United States and Europe of HIV-positive, ART-naive, AIDS-free individuals aged ≥18 years with baseline CD4 cell count and HIV RNA levels followed up from 1996 through 2007. We estimated hazard ratios (HRs) for cART versus no cART, adjusted for time-varying CD4 cell count and HIV RNA level via inverse probability weighting.<br />Results: Of 65 121 individuals, 712 developed tuberculosis over 28 months of median follow-up (incidence, 3.0 cases per 1000 person-years). The HR for tuberculosis for cART versus no cART was 0.56 (95% confidence interval [CI], 0.44-0.72) overall, 1.04 (95% CI, 0.64-1.68) for individuals aged >50 years, and 1.46 (95% CI, 0.70-3.04) for people with a CD4 cell count of <50 cells/μL. Compared with people who had not started cART, HRs differed by time since cART initiation: 1.36 (95% CI, 0.98-1.89) for initiation <3 months ago and 0.44 (95% CI, 0.34-0.58) for initiation ≥3 months ago. Compared with people who had not initiated cART, HRs <3 months after cART initiation were 0.67 (95% CI, 0.38-1.18), 1.51 (95% CI, 0.98-2.31), and 3.20 (95% CI, 1.34-7.60) for people <35, 35-50, and >50 years old, respectively, and 2.30 (95% CI, 1.03-5.14) for people with a CD4 cell count of <50 cells/μL.<br />Conclusions: Tuberculosis incidence decreased after cART initiation but not among people >50 years old or with CD4 cell counts of <50 cells/μL. Despite an overall decrease in tuberculosis incidence, the increased rate during 3 months of ART suggests unmasking IRIS.
- Subjects :
- AIDS-Related Opportunistic Infections microbiology
Adult
Anti-HIV Agents adverse effects
CD4 Lymphocyte Count
Cohort Studies
Developed Countries
Drug Therapy, Combination
Europe epidemiology
Female
HIV Infections virology
HIV Seropositivity drug therapy
HIV Seropositivity epidemiology
Humans
Immune Reconstitution Inflammatory Syndrome complications
Incidence
Male
Middle Aged
Mycobacterium tuberculosis isolation & purification
Pneumocystis carinii
Pneumonia, Pneumocystis epidemiology
Pneumonia, Pneumocystis microbiology
RNA, Viral analysis
Tuberculosis microbiology
United States epidemiology
Viral Load drug effects
AIDS-Related Opportunistic Infections epidemiology
Anti-HIV Agents therapeutic use
HIV Infections drug therapy
Tuberculosis epidemiology
Subjects
Details
- Language :
- English
- ISSN :
- 1537-6591
- Volume :
- 54
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
- Publication Type :
- Academic Journal
- Accession number :
- 22460971
- Full Text :
- https://doi.org/10.1093/cid/cis203